Sincerely, /s/ Philip Astley-Sparke Philip Astley-Sparke Chief Executive Officer July 27, 2022 |
By Order of the Board of Directors, /s/ Philip Astley-Sparke Philip Astley-Sparke Chief Executive Officer July 27, 2022 |
| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | | | ||
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | | | ||
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | | | ||
| | | | 18 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
Name | | | Age | | | Position(s) | | | Class | |
Philip Astley-Sparke | | | | | Chief Executive Officer and Director | | | I | | |
Robert Coffin, Ph.D. | | | | | President, Chief Research & Development Officer and Director | | | III | | |
Kapil Dhingra, M.B.B.S.(1)(2)(4) | | | | | Director | | | I | | |
Hyam Levitsky, M.D.(3)(4) | | | | | Director | | | III | | |
Christy Oliger(1)(4)(5) | | | 52 | | | Director | | | I | |
Paolo Pucci(2)(3)(4) | | | ||||||||
| | Director | | | II | | ||||
Joseph Slattery(1)(2) | | | | | Director | | | I | | |
Sander Slootweg | ||||||||||
| | | | Director | | | II | | ||
Dieter Weinand(1) | | | | | Director | | | III | |
Name: | | | Nominating and Corporate Governance Committee(1) | | | Compensation Committee | | | Audit Committee(2) | | | R&D Committee(3) | | ||||||||||||||
Kapil Dhingra, M.B.B.S. | | | | | | | | X | | | X | | |||||||||||||||
Hyam Levitsky, M.D. | | | X | | | | | | | | | X | | ||||||||||||||
Tanya Lewis | | | | | | | | | | | | X | | ||||||||||||||
| | | | | | | | X | | | X | | |||||||||||||||
| | X | | | X | | | | | | X | | |||||||||||||||
Jason Rhodes | | | | | | | | | | | | | |||||||||||||||
Joseph Slattery | | | | | | | | X | | | | | |||||||||||||||
| | ||||||||||||||||||||||||||
| | | | | | | | | | ||||||||||||||||||
Dieter Weinand | | | | | | | | | X | | | | |
| Board Diversity Matrix (as of July 1, 2022) | | ||||||||||||
| Total number of Directors | | | | | | | 9 | | | |
| | | Female | | | Male | | | Non- Binary | | | Did not Disclose Gender | |
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | 1 | | | 2 | | | 0 | | | 6 | |
Part II: Demographic Background | | | | | | | | | | | | | |
African American or Blank | | | 0 | | | 0 | | | 0 | | | 0 | |
Alaskan Native or Native American | | | 0 | | | 0 | | | 0 | | | 0 | |
Asian | | | 0 | | | 1 | | | 0 | | | 0 | |
Hispanic or Latinx | | | 0 | | | 0 | | | 0 | | | 0 | |
Native Hawaiian or Pacific Islander | | | 0 | | | 0 | | | 0 | | | 0 | |
White | | | 1 | | | 1 | | | 0 | | | 0 | |
Two or More Races or Ethnicities | | | 0 | | | 0 | | | 0 | | | 0 | |
LGBTQ+ | | | | | | | | | 0 | | | | |
Did Not Disclose Demographic Background | | | | | | | | | 6 | | | | |
Non-Employee Director | | | Annual Fee | | |||
Chairperson of the Audit Committee | | | | $ | 15,000 | | |
Member of the Audit Committee (other than chairperson) | | | | $ | 7,500 | | |
Chairperson of the Compensation Committee | | | | $ | 10,000 | | |
Member of the Compensation Committee (other than chairperson) | | | | $ | 5,000 | | |
Chairperson of the Nominating and Corporate Governance Committee | | | | $ | 8,000 | | |
Member of the Nominating and Corporate Governance Committee (other than chairperson) | | | | $ | 4,000 | | |
Chairperson of the Research & Development Committee | | | | $ | 10,000 | | |
Member of the Research & Development Committee (other than chairperson) | | | | $ | 5,000 | | |
Non-Employee Director | | | Annual Fee | | |||
Chairperson of the Audit Committee | | | | $ | 15,000 | | |
Member of the Audit Committee (other than chairperson) | | | | $ | 7,500 | | |
Chairperson of the Compensation Committee | | | | $ | 12,000 | | |
Member of the Compensation Committee (other than chairperson) | | | | $ | 6,000 | | |
Chairperson of the Nominating and Corporate Governance Committee | | | | $ | 10,000 | | |
Member of the Nominating and Corporate Governance Committee (other than chairperson) | | | | $ | 5,000 | | |
Chairperson of the Research & Development Committee | | | | $ | 12,000 | | |
Member of the Research & Development Committee (other than chairperson) | | | | $ | 6,000 | | |
Name | | Fees earned in cash ($)(1) | | Option Awards ($)(2) | | Total ($) | | | Fees earned in cash ($)(1) | | Option Awards ($)(2) | | Total ($) | | ||||||||||||||||||||||||
Kapil Dhingra, M.B.B.S. | | | | 54,153 | | | | | 103,841 | | | | | 157,994 | | | | | | 63,000 | | | | | 346,315 | | | | | 409,315 | | | ||||||
Hyam Levitsky, M.D. | | | | 42,306 | | | | | 103,841 | | | | | 146,148 | | | | | | 57,000 | | | | | 346,315 | | | | | 403,315 | | | ||||||
Tanya Lewis(3) | | | | 16,235 | | | | | 916,912 | | | | | 933,146 | | | | | | 4,699 | | | | | 346,315 | | | | | 351,014 | | | ||||||
Christy Oliger | | | | 17,834 | | | | | 618,275 | | | | | 636,109 | | | ||||||||||||||||||||||
Paolo Pucci | | | | 42,653 | | | | | 211,025 | | | | | 253,678 | | | | | | 57,000 | | | | | 346,315 | | | | | 403,315 | | | ||||||
Jason Rhodes | | | | 44,667 | | | | | 103,841 | | | | | 148,508 | | | | | | 50,000 | | | | | 346,315 | | | | | 396,315 | | | ||||||
Joseph Slattery | | | | 55,000 | | | | | 152,609 | | | | | 207,609 | | | | | | 61,000 | | | | | 346,315 | | | | | 407,315 | | | ||||||
Sander Slootweg | | | | 35,000 | | | | | 103,841 | | | | | 138,841 | | | | | | 40,000 | | | | | 346,315 | | | | | 386,315 | | | ||||||
Otello Stampacchia, Ph.D.(4) | | | | — | | | | | 103,841 | | | | | 103,841 | | | ||||||||||||||||||||||
Otello Stampacchia, Ph.D. | | | | 32,795 | | | | | 346,315 | | | | | 379,111 | | | ||||||||||||||||||||||
Dieter Weinand | | | | 74,000 | | | | | 155,762 | | | | | 229,762 | | | | | | 79,000 | | | | | 519,473 | | | | | 598,473 | | |
| | Option Awards | | | Option Awards | | ||||||||||||||
Name(1) | | Exercisable | | Unexercisable | | | Exercisable | | Unexercisable | | ||||||||||
Kapil Dhingra, M.B.B.S. | | 140,505 | | 18,205 | | | | | 158,710 | | | | | 16,500 | | | ||||
Hyam Levitsky, M.D. | | 37,110 | | 19,890 | | | | | 57,000 | | | | | 16,500 | | | ||||
Tanya Lewis(1) | | 0 | | 33,000 | | | | | 0 | | | | | 0 | | | ||||
Christy Oliger | | | | 0 | | | | | 33,000 | | | |||||||||
Paolo Pucci | | 0 | | 33,000 | | | | | 19,591 | | | | | 29,909 | | | ||||
Jason Rhodes | | 25,295 | | 18,205 | | |||||||||||||||
Jason Rhodes(2) | | | | 43,500 | | | | | 16,500 | | | |||||||||
Joseph Slattery | | 45,564 | | 30,325 | | | | | 75,889 | | | | | 16,500 | | | ||||
Sander Slootweg | �� | | 25,295 | | 18,205 | | | | | 43,500 | | | | | 16,500 | | | |||
Otello Stampacchia, Ph.D. | | 25,295 | | 18,205 | | |||||||||||||||
Otello Stampacchia, Ph.D.(3) | | | | 27,000 | | | | | 0 | | | |||||||||
Dieter Weinand | | 37,110 | | 28,140 | | | | | 65,250 | | | | | 24,750 | | |
Name | | | Age | | | Position(s) | |
Philip Astley-Sparke | | | | | Chief Executive Officer | | |
Robert Coffin, Ph.D. | | | | | President and Chief Research & Development Officer | | |
| | | | Chief | | ||
Jean Franchi | | | | | Chief Financial Officer and Treasurer | | |
Tanya Lewis | | | 51 | | | Chief Development Operation Officer | |
Colin Love, Ph.D. | | | | | Chief Operating | ||
| |||||||
Sushil Patel, Ph.D. | | | | | Chief Commercial | ||
|
Name and Principal Position | | | Year Ended | | | Base Salary ($) | | | Bonus ($) | | | Option Awards(1) ($) | | | Non-Equity Incentive Plan Compensation(2) ($) | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||
Philip Astley-Sparke | | | | | 2021 | | | | | | 533,000 | | | | | | — | | | | | | 1,698,067 | | | | | | 226,525 | | | | | | — | | | | | | 2,457,592 | | |
Chief Executive Officer | | | | | 2020 | | | | | | 437,754 | | | | | | — | | | | | | 1,541,213 | | | | | | 176,196 | | | | | | — | | | | | | 2,155,164 | | |
Robert Coffin, Ph.D. | | | | | 2021 | | | | | | 533,000 | | | | | | — | | | | | | 1,698,067 | | | | | | 226,525 | | | | | | — | | | | | | 2,457,592 | | |
President and Chief Research & Development Officer | | | | | 2020 | | | | | | 517,500 | | | | | | — | | | | | | 2,208,351 | | | | | | 208,294 | | | | | | — | | | | | | 2,934,145 | | |
Andrea Pirzkall(3) | | | | | 2021 | | | | | | 261,399 | | | | | | — | | | | | | 4,379,910 | | | | | | 85,262 | | | | | | — | | | | | | 4,726,571 | | |
Chief Medical Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Name and Principal Position | | | Year | | | Base Salary ($) | | | Bonus ($) | | | Stock Awards(1) ($) | | | Option Awards(1) ($) | | | Non-Equity Incentive Plan Compensation(2) ($) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||||||||
Philip Astley-Sparke Chief Executive Officer | | | | | 2022 | | | | | | 600,000 | | | | | | — | | | | | | 2,697,406 | | | | | | 2,788,372 | | | | | | 280,500 | | | | | | — | | | | | | 6,366,277 | | |
| | | 2021 | | | | | | 533,000 | | | | | | — | | | | | | — | | | | | | 1,698,067 | | | | | | 226,525 | | | | | | — | | | | | | 2,457,592 | | | ||
Robert Coffin, Ph.D. President and Chief Research & Development Officer | | | | | 2022 | | | | | | 551,500 | | | | | | — | | | | | | 2,427,397 | | | | | | 2,509,262 | | | | | | 234,388 | | | | | | — | | | | | | 5,722,547 | | |
| | | 2021 | | | | | | 533,000 | | | | | | — | | | | | | — | | | | | | 1,698,067 | | | | | | 226,525 | | | | | | — | | | | | | 2,457,592 | | | ||
Sushil Patel(3) Chief Commercial Officer | | | | | 2022 | | | | | | 394,167 | | | | | | — | | | | | | 3,246,238 | | | | | | 3,150,038 | | | | | | 152,650 | | | | | | 9,527 | | | | | | 6,952,619 | | |
| | | 2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name | | | Base Salary ($)(1) | | |||
Philip Astley-Sparke, Chief Executive Officer | | | | | | | |
Robert Coffin, Ph.D., President and Chief Research & Development Officer | | | | | | | |
| | | | | |
| | | Option Awards(1) | | |||||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | ||||||||||||
Philip Astley-Sparke | | | | | 82,060 | | | | | | 7,461(2) | | | | | | 3.30 | | | | | | 7/26/2027 | | |
| | | | | 93,320 | | | | | | 46,680(3) | | | | | | 15.00 | | | | | | 7/19/2028 | | |
| | | | | 73,330 | | | | | | 79,720(4) | | | | | | 15.50 | | | | | | 4/1/2029 | | |
| | | | | — | | | | | | 265,000(5) | | | | | | 9.78 | | | | | | 4/1/2030 | | |
Robert Coffin, Ph.D. | | | | | 291,734 | | | | | | 26,565(2) | | | | | | 3.30 | | | | | | 7/26/2027 | | |
| | Option Awards(1) | | | Option Awards(1) | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Exercise Date | | Number of Shares or Units of Stock that have not Vested (#) | | Market Value of Shares or Units of Stock that have not Vested | | ||||||||||||||||||||||||||||||||||||||||
| | | | 116,650 | | | | | 58,350(3) | | | | | 15.00 | | | | | 7/19/2028 | | | |||||||||||||||||||||||||||||||||||||||||
| | | | 105,073 | | | | | 114,227(4) | | | | | 15.50 | | | | | 4/1/2029 | | | |||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 265,000(5) | | | | | 9.78 | | | | | 4/1/2030 | | | |||||||||||||||||||||||||||||||||||||||||
Andrea Pirzkall | | | | — | | | | | 300,000(6) | | | | | 22.45 | | | | | 7/20/2030 | | | |||||||||||||||||||||||||||||||||||||||||
Philip Astley-Sparke | | | | | 89,521 | | | | | 0(2) | | | | | 3.30 | | | | | 7/26/2027 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||
| | | 128,312 | | | | | 11,688(3) | | | | | 15.00 | | | | | 7/19/2028 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | 111,586 | | | | | 41,464(4) | | | | | 15.50 | | | | | 4/1/2029 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | 126,970 | | | | | 138,030(5) | | | | | 9.78 | | | | | 4/1/2030 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | 0 | | | | | 128,125(6) | | | | | 31.58 | | | | | 4/1/2031 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | — | | | | | 85,415(7) | | | | | 2,697,406 | | | ||||||||||||||||||||||||||||||||
Robert Coffin, Ph.D. | | | | | 318,299 | | | | | 0(2) | | | | | 3.30 | | | | | 7/26/2027 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||
| | | 160,390 | | | | | 14,610(3) | | | | | 15.00 | | | | | 7/19/2028 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | 159,889 | | | | | 59,411(4) | | | | | 15.50 | | | | | 4/1/2029 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | 126,970 | | | | | 138,030(5) | | | | | 9.78 | | | | | 4/1/2030 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | 0 | | | | | 115,300(6) | | | | | 31.58 | | | | | 4/1/2031 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | — | | | | | 76,865(7) | | | | | 2,427,397 | | | ||||||||||||||||||||||||||||||||
Sushil Patel | | | | | 0 | | | | | 125,000(8) | | | | | 36.75 | | | | | 5/3/2031 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | — | | | | | 88,333(7) | | | | | 3,246,238 | | |
Fee Category | | 2020 | | 2021 | | | 2021 | | 2022 | | ||||||||||||||||
Audit Fees | | | $ | 879,000 | | | | $ | 962,000 | | | | | $ | 962,000 | | | | $ | 785,000 | | | ||||
Audit Related Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees | | | | 33,000 | | | | | 36,000 | | | | | | 36,000 | | | | $ | 43,000 | | | ||||
All Other Fees | | | | 1,000 | | | | | 1,000 | | | | | | 1,000 | | | | $ | 1,000 | | | ||||
Total Fees | | | $ | 913,000 | | | | $ | 999,000 | | | | | $ | 999,000 | | | | $ | 829,000 | | |
Beneficial Owner | | | Number of Shares Beneficially Owned† | | | Percentage of Shares Beneficially Owned (%) | | ||||||
Greater than 5% Stockholders: | | | | | | | | | | | | | |
Entities affiliated with Atlas Ventures(1) | | | | | 3,229,912 | | | | | | 6.9% | | |
FMR LLC(2) | | | | | 2,626,417 | | | | | | 5.6% | | |
Forbion Capital Fund III Coöperatief U.A(3) | | | | | 5,115,121 | | | | | | 10.9% | | |
Omega Fund IV, L.P.(4) | | | | | 5,256,917 | | | | | | 11.2% | | |
Redmile Group, LLC(5) | | | | | 4,743,286 | | | | | | 9.99% | | |
T. Rowe Price Associates, Inc.(6) | | | | | 2,625,691 | | | | | | 5.6% | | |
Named Executive Officers, Directors and Director Nominees | | | | | | | | | | | | | |
Philip Astley-Sparke(7) | | | | | 1,630,318 | | | | | | 3.5% | | |
Robert Coffin(8) | | | | | 2,376,046 | | | | | | 5.0% | | |
Andrea Pirzkall(9) | | | | | 82,250 | | | | | | * | | |
Kapil Dhingra(10) | | | | | 158,710 | | | | | | * | | |
Hyam Levitsky(11) | | | | | 57,000 | | | | | | * | | |
Paolo Pucci(12) | | | | | 12,374 | | | | | | * | | |
Jason Rhodes(13)(1) | | | | | 3,273,412 | | | | | | 7.0% | | |
Joseph Slattery(14) | | | | | 81,298 | | | | | | * | | |
Sander Slootweg(15)(3) | | | | | 5,158,621 | | | | | | 11.0% | | |
Otello Stampacchia(16)(4) | | | | | 5,300,417 | | | | | | 11.3% | | |
Dieter Weinand(17) | | | | | 62,500 | | | | | | * | | |
All executive officers, directors and director nominees as a group (16) persons)(18) | | | | | 19,956,687 | | | | | | 40.3% | | |
Beneficial Owner | | | Number of Shares Beneficially Owned† | | | Percentage of Shares Beneficially Owned (%) | | ||||||
Greater than 5% Stockholders: | | | | | | | | | | | | | |
Entities affiliated with Atlas Ventures(1) | | | | | 3,228,912 | | | | | | 6.8 | | |
Forbion Capital Fund III Coöperatief U.A(2) | | | | | 5,115,121 | | | | | | 10.7 | | |
Omega Fund IV, L.P.(3) | | | | | 4,435,385 | | | | | | 9.3 | | |
Redmile Group, LLC(4) | | | | | 4,824,872 | | | | | | 9.9 | | |
T. Rowe Price Associates, Inc.(5) | | | | | 5,868,638 | | | | | | 12.4 | | |
Named Executive Officers, Directors and Director Nominees | | | | | | | | | | | | | |
Philip Astley-Sparke(6) | | | | | 1,821,343 | | | | | | 3.8 | | |
Robert Coffin(7) | | | | | 2,581,329 | | | | | | 5.4 | | |
Sushil Patel(8) | | | | | 50,458 | | | | | | * | | |
Kapil Dhingra(9) | | | | | 175,210 | | | | | | * | | |
Hyam Levitsky(10) | | | | | 73,500 | | | | | | * | | |
Christy Oliger | | | | | 0 | | | | | | * | | |
Paolo Pucci(11) | | | | | 41,246 | | | | | | * | | |
Joseph Slattery(12) | | | | | 99,056 | | | | | | * | | |
Sander Slootweg(13)(2) | | | | | 5,175,121 | | | | | | 10.9 | | |
Dieter Weinand(14) | | | | | 90,000 | | | | | | * | | |
All executive officers, directors and director nominees as a group (14 persons)(15) | | | | | 11,967,745 | | | | | | 23.8 | | |